Document:

Prepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

EXHIBIT 10.34    
  

 
  AMENDMENT NO. 1 TO COLLABORATION AGREEMENT
  BETWEEN TULARIK INC. AND KNOLL AG    
  

    THIS AMENDMENT NO. 1 (this "Amendment") to the Collaboration Agreement dated as of November 1,
1998 (the "Agreement") by and between Knoll AG, a German corporation, having offices at Knollstrasse, 67061 Ludwigshafen, Germany ("Knoll"), and Tularik Inc., a Delaware corporation having offices at
Two Corporate Drive, South San Francisco, California 94080 ("Tularik"), is entered into as of August 15, 2000. Knoll and Tularik may be referred to herein as a "Party" or, collectively, as "Parties". 

    WHEREAS, the Parties previously entered into the Agreement, which provided for a collaboration between Knoll and Tularik to identify
proprietary compounds for development into Program Products; 

    WHEREAS, the Parties desire to modify the Agreement to amend the notice period necessary to terminate the Agreement; 

    WHEREAS, in order to accomplish the foregoing, the Parties have agreed to amend the Agreement in part; 

    NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements expressed herein, and for other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, Tularik and Knoll hereby agree as follows: 

    1.  Section
15.1 of the Agreement is hereby amended by deleting the first sentence and replacing it with the following: 

The
Collaboration Program shall be performed during the five year period following the Effective Date (the "Collaboration Program Term"); provided, however, that Knoll may terminate the Collaboration
Program on: (i) October 31, 2001, provided that Tularik receives written notice of such termination from Knoll prior to January 1, 2001; or (ii) October 31, 2002, provided that Tularik receives
written notice of such termination from Knoll prior to November 1, 2001. 

    2.  Capitalized
terms used herein but not otherwise defined herein shall have the respective meanings assigned to such terms in the Agreement. 

    3.  Except
as expressly modified by this Amendment, all of the terms and conditions of the Agreement shall remain in full force and effect. 

    4.  This
Amendment may be executed in two or more counterparts, each of which shall be deemed an original but all of which shall be considered one and the same
instrument. 

    IN WITNESS WHEREOF, the parties have executed, or caused their duly authorized officer or representative to execute, this Amendment as
of August 15, 2000. 

	TULARIK INC.	 	 
	

By:	
 	

  /s/ DAVID V. GOEDDEL   
	
 	

 
	Name: David V. Goeddel, Ph.D.

Title: Chief Executive Officer	 	 
	
KNOLL AG	
 	

 
	

By:	
 	

  /s/ DR. GOTTFRIED FRELER   
	
 	

 
	Name: Dr. Gottfried Freler

Title: General Counsel Legal and Taxes	 	 

1

QuickLinks

EXHIBIT 10.34

AMENDMENT NO. 1 TO COLLABORATION AGREEMENT BETWEEN TULARIK INC. AND KNOLL AGPrepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

EXHIBIT 10.35    
  

 
  AMENDMENT NO. 1 TO COLLABORATION AGREEMENT
  BETWEEN TULARIK INC. AND JAPAN TOBACCO INC.    
  

    THIS AMENDMENT NO. 1 (this "Amendment") to the Collaboration Agreement dated as of June 1, 2000
(the "Agreement") by and between Japan Tobacco, a Japanese corporation, having offices at JT Building, 2-1 Toranomon, 2-chome, Minato-ku, Tokyo 105, Japan ("JT"), and Tularik Inc., a Delaware
corporation having offices at Two Corporate Drive, South San Francisco, California 94080 ("Tularik"), is entered into as of January 1, 2001. JT and Tularik may be referred to herein as a
"Party" or, collectively, as "Parties". 

    WHEREAS, the Parties previously entered into the Agreement, which provided for a collaborative program between JT and Tularik to
research, discover, develop, manufacture and market products that agonize or antagonize various Program Targets for the treatment of disease in humans; 

    WHEREAS, Tularik has established the Subsidiary to conduct a portion of such collaborative program 

    WHEREAS, the Parties desire to modify the Agreement to provide for the purchase of certain technology; 

    WHEREAS, in order to accomplish the foregoing, the Parties have agreed to amend the Agreement in part; 

    NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements expressed herein, and for other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, Tularik and JT hereby agree as follows: 

    1.  Section
6.1 of the Agreement is hereby amended by inserting the following as Section 6.1(f): 

The
Parties agree that it is in the best interests of the Research Program for the Subsidiary to purchase approximately 104 kits containing 5,200 plates utilizing the  QuantigeneTM bDNA Signal
Amplification Assay technology (the "Kits") manufactured by Bayer AG. Tularik and JT shall share equally the costs
of the Kits, which costs are presently contemplated to equal approximately Five Hundred Thousand US Dollars (US$500,000.00) plus applicable taxes. Such Kits will be utilized for the screening of the
Current Program Targets. 

    2.  Capitalized
terms used herein but not otherwise defined herein shall have the respective meanings assigned to such terms in the Agreement. 

    3.  Except
as expressly modified by this Amendment, all of the terms and conditions of the Agreement shall remain in full force and effect. 

    4.  This
Amendment may be executed in two or more counterparts, each of which shall be deemed an original but all of which shall be considered one and the same
instrument. 

1

 

    IN WITNESS WHEREOF, the parties have executed, or caused their duly authorized officer or representative to execute, this Amendment as
of January 1, 2001. 

	TULARIK INC.	 	 
	

By:	
 	

  /s/ DAVID V. GOEDDEL   
	
 	

 
	Name: David V. Goeddel, Ph.D.

Title: Chief Executive Officer	 	 
	
JAPAN TOBACCO INC.	
 	

 
	

By:	
 	

  /s/ NORIAKI OKUBO   
	
 	

 
	Name: Noriaki Okubo

Title: Vice President, Business Development

Pharmaceutical Division	 	 

2

QuickLinks

EXHIBIT 10.35

AMENDMENT NO. 1 TO COLLABORATION AGREEMENT BETWEEN TULARIK INC. AND JAPAN TOBACCO INC.Prepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

EXHIBIT 10.36    
  

 
  AMENDMENT NO. 2 TO RESEARCH COLLABORATION AND LICENSE
  AGREEMENT BETWEEN TULARIK INC. AND SYNTEX (U.S.A.) LLC    
  

    THIS AMENDMENT NO. 2 (this "Amendment") to the Research Collaboration and License Agreement
dated as of July 8, 1997 (the "Agreement") by and between Syntex (U.S.A.) Inc., a Delaware corporation that has been merged into Syntex (U.S.A.) LLC, through its Roche Bioscience division, having
offices at 3401 Hillview Avenue, Palo Alto, California 94304 ("Roche Bioscience"), and Tularik Inc., a Delaware corporation having offices at Two Corporate Drive, South San Francisco, California 94080
("Tularik"), is entered into as of August 31, 2000. Roche Bioscience and Tularik may be referred to herein as a "Party" or, collectively, as "Parties." 

    WHEREAS, the parties previously entered into the Agreement, which provided for a collaboration between Roche Bioscience and Tularik to
discover proprietary Targets to use to identify proprietary compounds for development into Products; 

    WHEREAS, the parties desire to modify the Agreement to clarify the transfer of reagents between the parties; 

    WHEREAS, in order to accomplish the foregoing, the parties have agreed to amend the Agreement in part; 

    NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements expressed herein, and for other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, Tularik and Roche Bioscience hereby agree as follows: 

    1.  Article
5 of the Agreement is hereby amended by adding a new Section 5.8: 

    Section 5.8 Transfer of Reagents. If either Party (the "Transferring Party"), in the
exercise of such Party's sole discretion, transfers reagents to the other Party (the "Screening Party") after the date of this Amendment, the Screening
Party shall use such reagents solely in accordance with the terms of this Agreement. The Screening Party may use such reagents only at the Screening Party's place of business and in accordance with
the Research Plan. Any unused quantities of the reagents shall, no later than the end of the Tail Period, be returned to the Transferring Party or, upon written request by Transferring Party,
destroyed according to prescribed federal, state and local guidelines, including any written instructions received from the Transferring Party. THE TRANSFERRING PARTY DOES NOT MAKE ANY WARRANTY WITH
RESPECT TO THE REAGENTS. The Screening Party shall bear all risk and liability for all harm arising from its use of the reagents. Screening Party and Transferring Party as used in this Section shall
include such Party's Affiliates. 

    2.  Capitalized
terms used herein but not otherwise defined herein shall have the respective meanings assigned to such terms in the Agreement. 

    3.  Except
as expressly modified by this Amendment, all of the terms and conditions of the Agreement shall remain in full force and effect. 

    4.  This
Amendment may be executed in two or more counterparts, each of which shall be deemed an original but all of which shall be considered one and the same
instrument. 

1

 

    IN WITNESS WHEREOF, the parties have executed, or caused their duly authorized officer or representative to execute, this Amendment as
of August 31, 2000. 

	TULARIK INC.	 	 
	

By:	
 	

  /s/ DAVID V. GOEDDEL   
	
 	

 
	Name: David V. Goeddel, Ph.D.

Title: Chief Executive Officer	 	 
	
SYNTEX (U.S.A.) LLC,

THROUGH ITS ROCHE BIOSCIENCE DIVISION
	

By:	
 	

  /s/ JAMES N. WOODY   
	
 	

 
	Name: James N. Woody, M.D., Ph.D.

Title: President	 	 

2

QuickLinks

EXHIBIT 10.36

AMENDMENT NO. 2 TO RESEARCH COLLABORATION AND LICENSE AGREEMENT BETWEEN TULARIK INC. AND SYNTEX (U.S.A.) LLC

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00028-of-00352.parquet"}]]